8-K: Inogen Reports Preliminary Q4, Full-Year 2025 Revenue

Inogen, Inc. announced preliminary unaudited revenue results for the fourth quarter and full year 2025, showing modest growth despite a delay in some customer orders.

Summary

• Preliminary Q4 2025 revenue is approximately $82 million, a 2% year-over-year increase.
• Preliminary full-year 2025 revenue is approximately $349 million, a 4% year-over-year increase.
• The company expects to achieve positive Adjusted EBITDA for the full year 2025.
• A shift in timing of large customer orders into the first half of 2026 impacted Q4 results.
• Full-year highlights include positive revenue growth, progress towards profitability, and innovation pipeline expansion with Voxi 5 and Aurora Masks launches.

Sentiment

Score: 4

Explanation: The sentiment is mixed. While full-year revenue growth and positive Adjusted EBITDA are positives, the Q4 revenue growth was modest and impacted by a 'disappointing' delay in customer orders, indicating some operational challenges or missed short-term targets. The forward-looking statements are confident but lack specific numbers for 2026.

Positives

• Achieved positive revenue growth for the full year 2025 (4% year-over-year).
• Expects to achieve positive Adjusted EBITDA for the full year 2025, reflecting financial discipline.
• Strong performance observed in business-to-business channels during Q4.
• Expanded innovation pipeline with the launch of Voxi 5 stationary oxygen concentrator and Aurora Masks for Obstructive Sleep Apnea patients in the U.S.
• Management expresses confidence in driving growth acceleration and profitability into 2026.

Negatives

• Experienced a disappointing shift in the timing of a few large customer orders from Q4 2025 into the first half of 2026.
• Q4 2025 revenue growth was modest at approximately 2% year-over-year.
• The reported financial results are preliminary and unaudited, subject to change.

Risks

• Financial guidance may not be achieved.
• Market acceptance of products could be lower than anticipated.
• Competition in the medical technology and respiratory products market.
• Effectiveness of sales, marketing, and distribution capabilities.
• Risks associated with planned sales, marketing, and research and development activities.
• Risks associated with international operations.
• Preliminary, unaudited results are subject to change upon completion of audited financial statements.

Future Outlook

Inogen remains confident in its ability to drive growth acceleration and profitability into 2026. The company plans to provide additional details and 2026 financial guidance during its February 24, 2026 earnings call.

Management Comments

• "While fourth quarter results continued to reflect strong performance in our business-to-business channels, we experienced a shift in the timing of a few large customer orders into the first half of 2026."
• "While this delay relative to expectations is disappointing, our full year results continued to make meaningful progress in executing our business turnaround."
• "Highlights for the full year include positive revenue growth, advancing toward profitability, and expanding the innovation pipeline with launches of the Voxi 5 stationary oxygen concentrator and Aurora Masks for Obstructive Sleep Apnea patients in the U.S."
• "Our Inogen team remains confident in our ability to drive growth acceleration and profitability into 2026, and we look forward to sharing additional details and 2026 financial guidance during our February earnings call."

Industry Context

Inogen operates in the medical technology sector, specifically focusing on respiratory products for homecare. The launch of new products like the Voxi 5 oxygen concentrator and Aurora Masks indicates a continued effort to innovate and capture market share in the chronic respiratory conditions and sleep apnea segments, which are growing due to aging populations and increased prevalence of respiratory diseases.

Stakeholder Impact

• Shareholders: Preliminary results show modest growth but also a delay in orders, which could lead to short-term price volatility. The expectation of positive Adjusted EBITDA is a positive for profitability outlook.
• Customers: Large customer orders were delayed, indicating potential shifts in demand or fulfillment, but the B2B channel showed strong performance.
• Employees: Continued focus on business turnaround and innovation pipeline suggests ongoing strategic efforts.

Next Steps

• Complete the audit of financial statements for the year ended December 31, 2025.
• Host a conference call on February 24, 2026, to announce full Q4 and full-year 2025 financial results.
• Provide 2026 financial guidance during the February 24, 2026 earnings call.

Key Dates

Recommendation

The preliminary results show modest revenue growth and an expectation of positive Adjusted EBITDA, which are positive signs for a company undergoing a "business turnaround." However, the disappointing delay in Q4 orders and the preliminary nature of the results introduce uncertainty. Investors should hold and await the full audited financial results and 2026 guidance on February 24, 2026, for a clearer picture of the company's trajectory and future prospects before making further investment decisions.

Keywords

Inogen, INGN, Preliminary Revenue, Q4 2025, Full Year 2025, Adjusted EBITDA, Medical Technology, Respiratory Products, Homecare, Oxygen Concentrator, Sleep Apnea Masks, Earnings Guidance